Plasma p-tau217 predicts PET-based pathological staging for precision Alzheimer disease assessment.

ABSTRACT:

Introduction

While positron emission tomography (PET) is the standard for pathological staging, its limited availability necessitates accessible alternatives. We evaluated plasma biomarkers for detecting PET-based stages using single-axis (Thal/Braak) and integrated A/T composite models.

Methods

We enrolled 237 AD spectrum participants undergoing multimodal assessments including amyloid/tau PET and plasma biomarker analysis (phosphorylated tau [p-tau] 217, %p-tau217, and amyloid beta [Aβ] 42/40 ratio). Detecting and discriminative performance was assessed using receiver operating characteristics (ROC) analysis and probability-based stage prediction.

Results

Plasma p-tau217-based biomarkers showed excellent detecting performance for early amyloid (Thal I-II; area under

SUBMITTER: Kim HK 

PROVIDER: S-EPMC12910250 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature